| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | scaIM |
| Uniprot No | O52692 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-304aa |
| 氨基酸序列 | MSGRDFGYVIQSSAALWNRLSTFSQRGKALDTRLADIKKALGKPYYETSDVLLYHGDSLELLKSMPQQIFDLTVTSPPYNIGKEYEGVLSIEEYISWCETWMSRVHRATSAGGAFWLNVGYVPVPNQGKAVPIPYLLWDKSPFYMIQEVVWNYGAGVASRKSFSPRNEKFLWYVRDPLNYYFDLDSVRDPNVKYPNQKKNGKLKCNPLGKNPTDVWQFPKVTSGAKRSSVERTAHPAQFPSAVIERVIKACSPSDGVILDPFLGSGTTSLTARKQGRCSVGIEIREDYLDIAVGRLEAEAQSLF |
| 预测分子量 | 50.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于 **scaIM重组蛋白** 的虚构参考文献示例(基于常见重组蛋白研究框架)：
---
1. **文献名称**：*"Expression and Purification of Recombinant scaIM Protein in Escherichia coli"*
**作者**：Zhang, L. et al.
**摘要**：本研究成功构建了 **scaIM重组蛋白** 的原核表达系统，利用大肠杆菌BL21(DE3)进行诱导表达，并通过镍柱亲和层析纯化获得高纯度蛋白。实验验证了scaIM在体外具有免疫调节活性，为后续功能研究奠定基础。
2. **文献名称**：*"Structural Characterization of scaIM Recombinant Protein via X-ray Crystallography"*
**作者**：Lee, S. & Kim, J.
**摘要**：通过X射线晶体学解析了 **scaIM重组蛋白** 的三维结构，发现其具有独特的免疫球蛋白样结构域，并揭示了与靶标分子相互作用的潜在位点，为药物设计提供结构依据。
3. **文献名称**：*"scaIM Recombinant Protein Attenuates Inflammatory Response in Murine Sepsis Models"*
**作者**：Smith, R. et al.
**摘要**：在小鼠脓毒症模型中，外源性 **scaIM重组蛋白** 显著抑制促炎因子(如TNF-α、IL-6)释放，改善器官损伤，表明其在抗炎治疗中的应用潜力。
4. **文献名称**：*"Optimization of scaIM Production in Mammalian Cell Culture Systems"*
**作者**：Chen, Y. et al.
**摘要**：通过优化CHO细胞培养条件(如启动子选择、糖基化修饰)，实现 **scaIM重组蛋白** 的高效分泌表达，产量较传统方法提高3倍，适用于规模化生产。
---
注：以上文献为示例性质，具体研究需参考真实数据库(如PubMed、Web of Science)检索。若需实际文献支持，建议提供更精确的蛋白名称或研究背景。
**Background of scaIM Recombinant Protein**
scaIM recombinant protein is a engineered biomolecule designed for diverse biomedical and biotechnological applications. The term "scaIM" likely refers to a synthetic or chimeric protein construct, potentially combining functional domains from different parent proteins (e.g., receptors, enzymes, or binding motifs) to enhance stability, specificity, or multifunctionality. Recombinant proteins like scaIM are typically produced using recombinant DNA technology, where target gene sequences are cloned into expression vectors and expressed in host systems such as *E. coli*, yeast, or mammalian cells.
The development of scaIM may stem from the need to address limitations of natural proteins, such as poor solubility, short half-life, or immunogenicity. For instance, scaffold proteins or fusion tags (e.g., Fc regions, SUMO tags) are often incorporated to improve expression yields or facilitate purification. scaIM’s design might also include engineered binding sites for specific ligands, enabling applications in targeted drug delivery, diagnostics, or cellular signaling studies.
In research, scaIM could serve as a tool for studying protein-protein interactions, modulating immune responses, or acting as a therapeutic agent (e.g., in cancer therapy or autoimmune diseases). Its recombinant nature allows for customization, such as site-specific mutations or glycosylation pattern adjustments, to optimize functionality.
Challenges in scaIM production include ensuring proper folding, post-translational modifications, and scalability. Advances in synthetic biology and AI-driven protein design have accelerated the optimization of such proteins, balancing stability and activity.
Overall, scaIM exemplifies the intersection of protein engineering and translational science, offering tailored solutions for complex biological challenges while underscoring the versatility of recombinant protein technology.
×
